Signaling pathways
-
BA6336 ZenocutuzumabSummary: Zenocutuzumab (MCLA-128) is a bispecific humanized antibody. - BA6337 RezivertinibSummary: Rezivertinib (BPI-7711) is an orally effective, highly selective and irreversible third-generation tyrosine kinase inhibitor (TKI).
- BA6338 BI-4142Summary: BI-4142 is a potent and highly selective inhibitor with oral activity.
- BA6339 SimotinibSummary: Simotinib is a selective, specific, and orally bioavailable tyrosine kinase inhibitor.
- BA6340 EGFR-IN-3Summary: EGFR-IN-3 is a potent inhibitor.
- BA6341 NSC689857Summary: NSC689857 is a potent inhibitor.
- BA6342 EGFR-IN-7Summary: EGFR-IN-7 is a potent and selective kinase inhibitor with oral activity.
- BA6343 MTX-211Summary: MTX-211 (Mol211) is a dual inhibitor.
- BA6344 CH7233163Summary: CH7233163 is a -Del19/T790M/C797S non-covalent ATP competitive inhibitor.
- BA6345 BefotertinibSummary: Befotertinib (D-0316) is a third generation tyrosine kinase inhibitor.